|Cost-Effectiveness Tool for Evaluating Interventions to Prevent Mother-to-Child Transmission - Manual and Model (UNAIDS, 2000, 94 p.)|
|PUBLISHED STUDIES AND OTHER RESOURCES|
Clinical trials and HIV transmission rates
Centers for Disease Control and Prevention. 1998. Administration of zidovudine during late pregnancy to prevent perinatal HIV transmission - Thailand 1996-98. Morb Mortal Wkly Rep. 1998;47:151-153.
Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Paediatric AIDS Clinical Trials Group Protocol 076 Study Group. New Engl J Med 1994; 331: 1173-80.
Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Olivier M et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovidine to reduce vertical transmission of HIV in breastfed children in Cote dIvoire and Burkino Faso: a double-blind placebo-controlled multicentre trial. The Lancet 1999;353:786-792.
Dabis F, Msellati P, Dunn D, et al. Estimating the rate of mother-to-child transmission of HIV. Report of a workshop on methodological issues Ghent (Belgium), 17-120 February 1992. AIDS. 1993;7:1139-1148.
Guay LA, Musoke, P, Fleming T, Bagenda, D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve, M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda. The Lancet, 1999; 354 (9181):795-802.
Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999;353:773-780.
Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote dIvoire: a randomised trial. Lancet 1999;353:781-785.
The Working Group on mother-to-child transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J AIDS Hum Retrovirology 1995; 8: 506-10.
Kinghorn AW. Projections of the costs of anti-retroviral interventions to reduce mother-to-child transmission of HIV in the South African Public Sector. Johannesburg: HIV Management Services Technical Report, 1998.
Lutter C. Mother-to-Child Transmission of HIV in the Dominican Republic: Estimated Population Attributable Risk and Cost of the Integrated Preventive Package. Washington, D.C.: PAHO; 1998.
Mansergh G, Haddix AC, Steketee RW, Nieburg PI, Hu DJ, Simonds RJ et al. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-saharan African developing country setting. JAMA 1996;276:139-145.
Mansergh G, Haddix AC, Steketee RW, Simonds RJ. Cost-effectiveness of zidovudine to prevent mother-to-child transmission of HIV in sub-Saharan Africa. JAMA 1998; 280; 30-31.
Marseille E, Kahn JG, Saba J. Cost-effectiveness of anti-retroviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS 1998; 12: 939-948.
Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, Jackson JB. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa, in The Lancet, 1999; 354 (9191) 803-809.
Mauskopf, JA, JE Paul, DS Wichman, AD White, HH Tilson. 1996. Economic Impact of Treatment of HIV-Positive Pregnant Women and Their Newborns with Zidovidine. JAMA 1996;276:132-138.
Newell, M-L, F Dabis, K Tolley, D Whynes for the Ghent International Working Group on Mother-to-Child Transmission of HIV. 1998. Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. AIDS 1998, 12:1571-1580.
Ratcliffe J, Ades AE, Gibb D, Sculpher MJ, Briggs AH. Prevention of mother to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness. AIDS 1998;12:1381-1388.
Soderlund, N., et al., Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa. BMJ, 1999. 318(7199): p. 1650-6.
Wilkinson D, Floyd K, Gilks CF. Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity. AIDS 1998 (in press).
Thaineua, V, P Sirinirand, A Tanbanjong, M Lallemant, A Soucat, and J-L Lamboray. 1998. From efficacy to effectiveness: routine prevention of mother-to-child HIV transmission by a short course of zidovudine in Northern Thailand. South East Asian J of Trop Med and Pub Health. September 1998. NOTE: This study contains data on adherence to regimen.
UNAIDS 1998b. Mother-to-child transmission of HIV. UNAIDS Technical update. UNAIDS Best Practice Collection, October 1998.
UNAIDS. 1998. Prevention of HIV Transmission from Mother-to-Child: Meeting on Planning for Programme Implementation (Meeting Statement, Geneva, 23-24 March 1998). http://www.unaids.org/highband/document/statement/mtcstat.html.
UNAIDS. Prevention of HIV transmission from mother to child. Planning for programme implementation. Geneva: UNAIDS, 1998.
UNAIDS and Wold Health Organization. Guidance Modules on Antiretroviral Treatments - Module 2. Introducing Antiretroviral Treatments into Health Systems: Economic Considerations. Geneva: UNAIDS & WHO, 1998.
UNAIDS and Wold Health Organization. Guidance Modules on Anti-retroviral Treatments - Module 6. The Use of Antiretroviral drugs to Reduce Mother to Child Transmission of HIV. Geneva: UNAIDS & WHO, 1998
World Health Organization. 1998. Recommendations on the safe and effective use of short-course ZDV for prevention of mother-to-child transmission of HIV. Weekly Epidemiological Record 1998, 73, 313-320.
Acceptance of ARVs
Seals, BF, M Hennessey, R Sowell. 1996. Factors influencing acceptance and adherence to zidovudine treatment to prevent vertical transmission of HIV. Int Conf AIDS. 1996 Jul 7-12;11(1):368(abstract no. Tu.C.2594).